Vivani Medical (VANI) Income from Continuing Operations (2014 - 2026)
Vivani Medical (VANI) posted quarterly Income from Continuing Operations of 9973000.0 for Q1 2026, up 70.22% year-over-year from 5859008.46 in Q1 2025, and up 87.93% quarter-over-quarter from 82637000.0 in Q4 2025.
Vivani Medical (VANI) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Vivani Medical's Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 9973000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 70.22% year-over-year to 9973000.0; the TTM figure through Mar 2026 stood at 117456000.0 (up 15.74% YoY), while the FY2025 annual figure was 103383000.0, down 9.68% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 9973000.0, up from 82637000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 3950000.0 in Q1 2022, with the low at 82637000.0 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 14763000.0 (2024), against an average of 25080058.82.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations surged 93.05% in 2022, then tumbled 1303.49% in 2024.
- Vivani Medical's Income from Continuing Operations stood at 62624000.0 in 2022, then surged by 91.35% to 5418000.0 in 2023, then sank by 1303.49% to 76041000.0 in 2024, then fell by 8.67% to 82637000.0 in 2025, then surged by 87.93% to 9973000.0 in 2026.
- Business Quant data shows VANI's Income from Continuing Operations at 9973000.0 in Q1 2026, 82637000.0 in Q4 2025, and 9790000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Vivani Medical | 120.18 Mn | 100.29 Mn | - | -6.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.86 Mn |
| Mar 31, 2026 | -9.97 Mn |
| Dec 31, 2025 | -82.64 Mn |
| Sep 30, 2025 | -9.79 Mn |
| Jun 30, 2025 | -15.06 Mn |
| Mar 31, 2025 | -33.49 Mn |
| Dec 31, 2024 | -76.04 Mn |
| Sep 30, 2024 | -15.11 Mn |
| Jun 30, 2024 | -14.76 Mn |
| Mar 31, 2024 | -36.25 Mn |
| Dec 31, 2023 | -5.42 Mn |
| Sep 30, 2023 | -7.14 Mn |
| Jun 30, 2023 | -37.99 Mn |
| Mar 31, 2023 | -6.60 Mn |
| Dec 31, 2022 | -62.62 Mn |
| Sep 30, 2022 | -5.44 Mn |
| Jun 30, 2022 | -4.09 Mn |
| Mar 31, 2022 | -3.95 Mn |
| Dec 31, 2021 | -901.29 Mn |
| Sep 30, 2021 | -3.54 Mn |